Guanfacine: Clinical Overview
Guanfacine is a second-line non-stimulant medication for ADHD in children and adolescents, dosed at 0.1 mg/kg once daily (typically 1-4 mg), with primary indications when stimulants are unsuitable, not tolerated, or ineffective. 1
Indications
Primary Indication: ADHD
- Second-line treatment for ADHD in children and adolescents when stimulants are not suitable, not tolerated, or have been shown ineffective 1
- Available as extended-release formulation for once-daily dosing 1
- Can be used as monotherapy or adjunctive therapy with stimulants (FDA-approved for adjunctive use in the US) 1, 2
Special Populations
- First-line consideration in patients with comorbid disruptive behavior disorders, tic disorder, or Tourette's syndrome 1
- Not recommended for preschool-aged children (4-5 years) due to insufficient evidence 2, 3
Regional Approval Differences
- Europe: Only approved when stimulants are not suitable, not tolerated, or ineffective 1
- US: Approved as monotherapy or adjunctive therapy with stimulants 2
Dosing Regimen
Starting and Maintenance Dosing
Weight-based dosing is recommended: 0.1 mg/kg once daily as a rule of thumb 1
- Available tablet strengths: 1,2,3, and 4 mg 1
- Starting dose: 1 mg once daily 1
- Titration: Increase by 1 mg weekly based on response and tolerability 4
- Target dose range: 0.05-0.12 mg/kg/day or 1-7 mg/day 4
- Maximum dose: 4 mg/day in children; up to 6-7 mg/day documented in some guidelines 5
Administration Timing
- Evening administration generally preferable due to somnolence/fatigue as common adverse effects 1
- Once-daily dosing provides "around-the-clock" effects 1
Time to Effect
Treatment effects typically not observed until 2-4 weeks after initiation 1 - significantly delayed compared to stimulants which have rapid onset
Monitoring Requirements
Cardiovascular Monitoring
Monitor heart rate and blood pressure regularly due to risk of bradycardia and hypotension 2, 3
- Obtain personal and family cardiac history before initiation 3
- Consider ECG if cardiac risk factors present 3
- Monitor vital signs at baseline and during treatment 2
Growth Monitoring
- Less impact on growth compared to stimulants 1
- Routine growth monitoring still recommended as standard ADHD care
Clinical Response Monitoring
- Assess ADHD symptom improvement at 2-4 weeks minimum 1
- Monitor for functional impairment and quality of life improvements 1
- Long-term maintenance of treatment effects documented 1
Side Effects
Most Common Adverse Effects
The most frequent side effects are somnolence, fatigue, irritability, insomnia, and nightmares 1
Specific incidence from FDA label data 6:
- Somnolence: 10-39% (dose-dependent)
- Dry mouth: 10-54% (dose-dependent)
- Fatigue: 9-10%
- Dizziness: 8-15%
- Headache: 4-13%
- Constipation: 10-16%
- Abdominal pain: Common 2
Serious Warnings
Critical warnings include hypotension/bradycardia, cardiac conduction abnormalities, and rebound hypertension with abrupt discontinuation 1, 2
- Cardiovascular effects: Bradycardia, hypotension, syncope 1, 2, 6
- Rebound hypertension: Occurs after abrupt discontinuation - must taper rather than suddenly discontinue 2, 3
- Allergic reactions 1
Comparative Safety Profile
- Less sedative effects than clonidine due to higher specificity for alpha-2A receptors 1
- Adverse effects less frequent and less pronounced compared to clonidine 1
- Lower incidence of withdrawal symptoms compared to clonidine 7
Mechanism of Action
Guanfacine is an alpha-2A adrenergic receptor agonist that enhances noradrenergic neurotransmission in the prefrontal cortex, strengthening top-down guidance of attention, thought, and working memory 1
Pharmacokinetics
- Metabolism: Primarily via CYP3A4 1
- Excretion: Predominantly renal 1
- Potency: Approximately 10 times less potent than clonidine 1
Efficacy Considerations
Comparative Effectiveness
Guanfacine has medium effect sizes compared to placebo, smaller than stimulants 1
- Meta-analysis shows significant efficacy: 58.5% response with guanfacine vs 29.4% with placebo at <10 weeks 8
- Improves core ADHD symptoms, functional impairment, and quality of life 1
- Current guidelines recommend as second-line after stimulants due to smaller effect sizes 1
Clinical Pitfalls to Avoid
- Do not abruptly discontinue - taper to avoid rebound hypertension 2, 3
- Do not expect immediate effects - allow 2-4 weeks for therapeutic response 1
- Monitor for excessive sedation - consider evening dosing 1
- Screen for cardiac risk factors before initiation 3
- Be aware of CYP3A4 interactions - guanfacine levels affected by strong inhibitors/inducers 1